136 related articles for article (PubMed ID: 11096218)
21. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
[TBL] [Abstract][Full Text] [Related]
22. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
23. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
[TBL] [Abstract][Full Text] [Related]
24. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
25. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
26. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
27. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.
Pulicken M; Bash CN; Costello K; Said A; Cuffari C; Wilterdink JL; Rogg JM; Mills P; Calabresi PA
Mult Scler; 2005 Apr; 11(2):169-74. PubMed ID: 15794390
[TBL] [Abstract][Full Text] [Related]
28. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
29. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
30. Education and self-management of interferon beta-1b therapy for multiple sclerosis.
Keating MM; Ostby PL
J Neurosci Nurs; 1996 Dec; 28(6):350-2, 357-8. PubMed ID: 9007762
[TBL] [Abstract][Full Text] [Related]
31. Editorial commentary to Narayanan et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.
Matthews PM
J Neurol; 2001 Nov; 248(11):987. PubMed ID: 11757964
[No Abstract] [Full Text] [Related]
32. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
[TBL] [Abstract][Full Text] [Related]
33. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
Lacy M; Hauser M; Pliskin N; Assuras S; Valentine MO; Reder A
Mult Scler; 2013 Nov; 19(13):1765-72. PubMed ID: 23652214
[TBL] [Abstract][Full Text] [Related]
34. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
[TBL] [Abstract][Full Text] [Related]
35. Early treatment and dose optimisation BENEFIT and BEYOND.
Hartung HP
J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
[TBL] [Abstract][Full Text] [Related]
36. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
[TBL] [Abstract][Full Text] [Related]
37. [Auditory evoked potentials in patients with schizophrenia and affective disorders].
Lebedeva IS; Abramova LI; Bondar' VV; Kaleda VG; Oleĭchik IV; Tsutsul'kovskaia MIa
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(1):56-60. PubMed ID: 11842625
[TBL] [Abstract][Full Text] [Related]
38. The auditory system involvement in Parkinson disease: electrophysiological and neuropsychological correlations.
Nojszewska M; Pilczuk B; Zakrzewska-Pniewska B; Rowińska-Marcińska K
J Clin Neurophysiol; 2009 Dec; 26(6):430-7. PubMed ID: 19952569
[TBL] [Abstract][Full Text] [Related]
39. Multiple sclerosis: what have we learned from magnetic resonance imaging studies?
Khoury SJ; Weiner HL
Arch Intern Med; 1998 Mar; 158(6):565-73. PubMed ID: 9521220
[TBL] [Abstract][Full Text] [Related]
40. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
